Scientists map key enzyme linked to rare metabolic disorder glutaric aciduria type 1
Researchers at the Icahn School of Medicine at Mount Sinai have mapped the complete structure of the AASS enzyme, offering new structural insights that could guide future drug development for glutaric aciduria type 1 (GA1).
🥗NutritionPhoto: Medical Xpress
Key points
- Icahn School of Medicine researchers mapped the complete structure of the AASS enzyme.
- The study identifies a flexible hinge region that regulates enzyme activity, offering a potential drug target for GA1.
- Findings are early-stage laboratory results; further animal and human studies are required.
A team of investigators at the Icahn School of Medicine at Mount Sinai has successfully mapped the full structure of the enzyme AASS, which plays a central role in breaking down the amino acid lysine. Published in Science Advances, the study reveals how specific regulatory regions control the enzyme's activity, potentially paving the way for targeted therapies against glutaric aciduria type 1 (GA1), a rare inherited metabolic condition.
GA1 causes toxic metabolites to accumulate inside the body, which can trigger irreversible brain damage and severe neurological complications. By isolating the complete human enzyme and utilizing advanced techniques such as cryo-electron microscopy alongside computer simulations, the researchers generated high-resolution visualizations of AASS. They discovered a hinge-like region where minor structural adjustments significantly alter the protein's function, offering a promising target for future drug inhibitors.
The study authors emphasize that these findings represent an early laboratory step rather than a proven treatment or cure. Because the work was conducted in vitro, subsequent investigations involving animal and eventually human studies will be necessary to establish safety and clinical efficacy. Readers should consult qualified healthcare professionals regarding personal medical questions or genetic conditions.
- What to know: Mount Sinai researchers mapped the structure of the AASS enzyme to better understand lysine breakdown and explore drug targets for GA1.
- Study methods: Scientists used cryo-electron microscopy, biochemical experiments, and computer simulations to analyze the enzyme.
- Limitations: The findings are strictly early-stage laboratory results and do not constitute a cure or available treatment.
Source Medical Xpress — medicalxpress.com/news/2026-11-enzyme-clues-rare-genetic-disease.html ↗
Read next
🧠Mind & Mental HealthAddressing Body Image and the Reality of Gluteal Anatomy
A personal reflection on the social and psychological impact of body shape, specifically regarding the gluteal region, and the limitations of consumer solutions for perce…
❤️Conditions & CareMigraine and Smoking Linked to Increased Early Stroke Risk in Women
A large-scale study suggests that people who have given birth and experience migraines while also smoking face a significantly higher risk of stroke before age 60.
🔬ResearchCBD Oil Found Ineffective for Managing Behavioral Issues in Youths with Intellectual Disabilities
A double-blind clinical trial published in JAMA Pediatrics indicates that CBD oil provides no significant behavioral improvement for children and teenagers with intellect…
🏃FitnessExpert Advice on Hydration Gear Sparks Debate Among Recreational Runners
Olympic medalist Josh Kerr recently suggested that runners may not require hydration packs for distances under 12 miles, igniting a broader conversation about gear necess…
🏃FitnessA Structured Approach to Beginning a Strength and Cardio Routine
A new four-week training program offers beginners a guided path to incorporating strength training and cardiovascular exercise into their daily lives.
🧠Mind & Mental HealthThe Role of Daily Mobility Training in Managing Sedentary Tension
A two-week personal trial suggests that incorporating short, daily mobility exercises may help alleviate stiffness associated with sedentary desk work. Experts note that …